The effect of hormone replacement therapy on postmenopausal bone loss

Area of Science:

• Endocrinology
• Bone Metabolism
• Postmenopausal Health

Background:

• Postmenopausal osteoporosis is a significant health concern.
• Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms and bone loss.

Purpose of the Study:

• To compare the effects of different HRT regimens on bone mineral content and biochemical markers in postmenopausal women.
• To evaluate continuous conjugated estrogens (CE) versus cyclic CE and transdermal 17 beta-estradiol therapies.

Main Methods:

• Eighty-four postmenopausal women were randomized into four groups: cyclic CE, continuous CE, cyclic transdermal estradiol, and a control group.
• Bone mineral content was measured using dual photon absorptiometry at baseline and after 1 year.
• Serum calcium, phosphate, osteocalcin, and urinary calcium/creatinine and hydroxyproline/creatinine ratios were measured at baseline, 6, and 12 months.

Main Results:

• All HRT groups showed an increase in bone mineral content.
• Continuous CE therapy resulted in a 4.4% increase (P<0.05), while transdermal estradiol showed a 7.1% increase (P<0.01).
• Biochemical markers indicated reduced bone turnover and calcium excretion in HRT groups.

Conclusions:

• Continuous CE and transdermal estradiol therapies are effective in increasing bone mineral content in postmenopausal women.
• HRT, particularly continuous CE and transdermal estradiol, positively impacts bone metabolism and reduces bone loss.
• These findings support the use of specific HRT regimens for managing postmenopausal bone health.